Latest Content

In a world of unfamiliarity and uncertainty, patient advocates help guide those with cancer through challenging diagnoses and the decisions that come with them.

Nurses are called to honor Alex Pretti’s memory through compassion and action.

The FDA approved a larger vial size of nelarabine for the treatment of pediatric and adult patients with T-ALL and T-LBL.

Updates in ovarian cancer include multiple fast track designations and breakthrough therapy status for new drugs in the clinical space.

The FDA approved subcutaneous daratumumab/VRd in patients with newly diagnosed multiple myeloma who are not eligible for ASCT. Here’s what you should know.

Plus, a phase 1 breast cancer vaccine, updated NCCN guidelines, and a combination with standard-of-care potential in triple-negative breast cancer.

The frontline combination of nivolumab and ipilimumab demonstrated long-term safety and efficacy in patients with unresectable hepatocellular carcinoma.

Kelly Grosklags, LICSW, BCD, FAAGC, FT, shares insights for dealing with grief as an oncology clinician.

Chemoradiotherapy led to OS and RFS benefit in patients with high-risk chemoradiotherapy vs radiotherapy alone.

A 5-day NYC nurses' strike raises concerns about staffing, patient safety, and the critical role of oncology nurses in cancer care.

The FDA granted JSKN003 breakthrough therapy status for gynecologic cancers based on data from the phase 1 JSKN003-101 and phase 1/2 JSKN003-102 trials.

When patients with RCC progress on a TKI/IO combination, advanced practice providers use patient experience to inform treatment decisions.

Elizabeth Lee, MD, shares that rinatabart sesutecan’s mechanism of action may allow more patients with advanced endometrial cancer to receive effective treatment.